SUMMARY Fourteen consecutive patients with chronic inflammatory rheumatic disease and reactive renal amyloidosis were treated with alkylating cytostatics in 22 separate periods varying in duration between six and 30 months. Chlorambucil alone was given in 14 treatment periods, cyclophosphamide alone in six, and both alternately in two. The dosage was adjusted to attain a major suppression of the rheumatic inflammation and a blood lymphocyte level below 1-0 x 109/l.
regression of renal amyloidosis was found after treatment with Cy. 8 In the present study 14 patients with rheumatic disease and reactive renal amyloidosis were treated with Cy or Ch, or both, in a total of 22 separate treatment periods. The results suggest an ameliorating effect on the course of the renal process. Experience from several other cases with shorter observation periods appears to corroborate this finding.
Patients and methods
Fourteen consecutive patients with rheumatic disease and renal amyloidosis (Table 1) were treated with Ch or Cy, or both (Table 2) . Nine had rheumatoid arthritis, one had JCA, and four had ankylosing spondylitis. The amyloidosis was verified by biopsies (Table 1) .
All patients had proteinuria with or without nephrotic syndrome (Table 1) , and all but two showed substantially decreased kidney function (Table 2) .
Serum creatinine and endogenous creatinine clearance were determined by routine methods, and in most instances the GFR was assessed as 5 Cr- 
cytostatic drug (P(RF), Table 2 ); three of these four periods are included in Fig. 1 . There was no regular pattern of change in CRP in periods classified as S or P(RF).
In the remaining three periods the rate of deterioration of renal function did not change (P, Table 2 ). In all of these, treatment was inadequate in some respect. In period 1, 
the treatment programme and lost contact with the department some time before they entered end stage of their renal disease (Table 2) . Median survival time is now seven years (range 4-5-17) .
None of the patients has so far shown any potentially fatal side effects of the treatment with alkylating agents. Herpes zoster occurred in 4/22 periods, necessitating the interruption of therapy for a couple of months.
Discussion
In the 14 patients followed up the five year survival rate was 93%, significantly more than the 50% (p<0.01) which is characteristic for the natural course of renal amyloidosis secondary to rheumatic disease.4 5 The mean survival time is now nine years, a figure that will rise as two patients are in full remission with regard to arthritis and renal affection, and seven patients (i.e., excluding two living with renal transplants) have not yet reached the end stage of renal disease. The three patients who died of uraemia might have lived longer had they continued with the treatment programme.
The unexpectedly favourable trend in survival statistics is corroborated by analysis of the laboratory data ( Table 2 , Fig. 1 
